Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.

Abstract

A transplantable hepatocarcinoma of strain 2 guinea pigs was used as an experimental model for immunotherapy of cancer. 6,6'-Dideoxy-6,6'-bis-mycoloylamino-alpha,alpha- trehalose (TDNM) was found to be more effective in producing regression of transplantable line-10 tumours than 6,6'-di-O-mycoloyl-alpha,alpha-trehalose (TDM) when combined with 6-O-stearoyl muramyldipeptide (L18-MDP). TDNM showed potent antitumour activity in combination with synthetic lipid A of Escherichia coli (compound 506), but not with the lipid A analogues (GLA-59 and 60). As with the combination of MDP derivative and lipid A analogue, MDP derivatives conjugated with GLA-60 (GMD compounds) showed no tumour regression activity of line-10 cells in guinea-pigs.

• Authors: H Ishida, I Saiki, S Saito, A Hasegawa, M Kiso, I Azuma
• Journal: Vaccine (Vaccine) Vol. 6 Issue 5 Pg. 440-4 (Oct 1988) ISSN: 0264-410X [Print] Netherlands
• PMID: 3195200 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Adjuvants, Immunologic
• Cord Factors
• Lipid A
• GLA 60
• Acetylmuramyl-Alanyl-Isoglutamine
• romurtide

Topics

• Acetylmuramyl-Alanyl-Isoglutamine (administration & dosage, analogs & derivatives)
• Adjuvants, Immunologic (administration & dosage)
• Animals
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Cord Factors (administration & dosage)
• Guinea Pigs
• Lipid A (administration & dosage, analogs & derivatives)
• Liver Neoplasms (pathology, therapy)
• Liver Neoplasms, Experimental (pathology, therapy)
• Remission Induction